Clinical Trial Update: Safety Study for Beta Thalassemia Subjects on PTG-300 [Phase 2]

View source ↗

Summary

Phase 2 safety study for PTG-300 in beta-thalassemia subjects completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Ineffective Erythropoiesis

Drugs mentioned

• PTG-300

Snippet

Sponsor: Protagonist Therapeutics, Inc. | Conditions: β-thalassemia, Ineffective Erythropoiesis | Phase 2 | Status: COMPLETED